Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05737485 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
A Phase 1 study, sponsored by ReCode Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05737485 is a Phase 1 study that has completed, run by ReCode Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT05737485, a Phase 1 study, has completed, sponsored by ReCode Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.
Interventions
- DRUG RCT1100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-02-18 |
| Est. Completion | 2025-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05737485
The ClinicalTrials.gov registry entry for NCT05737485 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReCode Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RCT1100 is the first listed.
NCT05737485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05737485 about?
NCT05737485 is a clinical study titled "Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects". This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.
What is the current status of trial NCT05737485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-02-18. Estimated completion is 2025-01-13.
What interventions are being tested in trial NCT05737485?
The interventions under investigation include: RCT1100 (DRUG).
Who is sponsoring clinical trial NCT05737485?
This trial is sponsored by ReCode Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.